Clinical background of study participants: full analysis set
| ASV (n=19) | Oxygen (n=21) | p Value | |
|---|---|---|---|
| Male, n (%) | 17 (89.4) | 17 (81.0) | 0.44 |
| Age, years | 68±9 | 69±9 | 0.91 |
| Body mass index, kg/m2 | 22.9±2.9 | 24.7±2.4 | 0.04 |
| NYHA classification (I/II/III), n | 0/14/5 | 1/14/6 | 0.50 |
| Main aetiology of heart failure | |||
| Old myocardial infarction, n (%) | 10 (52.6) | 10 (47.6) | |
| Dilative cardiomyopathy, n (%) | 9 (47.4) | 9 (42.8) | |
| Hypertrophic cardiomyopathy, n (%) | 0 (0) | 1 (4.8) | |
| Sarcoidosis, n (%) | 0 (0) | 1 (4.8) | 0.47 |
| History of atrial fibrillation (%) | 4 (21.1) | 3 (14.3) | 0.69 |
| Medication | |||
| β-blocker, n (%) | 14 (73.7) | 18 (85.7) | 0.44 |
| Diuretics, n (%) | 10 (52.6) | 10 (47.6) | 1.00 |
| Ca-blocker, n (%) | 3 (15.8) | 3 (14.3) | 1.00 |
| ACE inhibitor/ARB, n (%) | 13 (68.4) | 17 (81.0) | 0.47 |
| Amiodarone, n (%) | 2 (10.5) | 1 (4.8) | 0.60 |
| Implanted biventricular pacemaker or cardiac defibrillator, n (%) | 4 (21.1) | 3 (14.3) | 0.58 |
| NT-proBNP, pg/mL | 1200 (356–1720) | 446 (195–1160.5) | 0.10 |
| Apnoea hypopnoea index, /h | 34.2±12.1 | 36.9±9.9 | 0.45 |
| Central/total apnoea hypopnoea index, per cent | 83.1±15.7 | 73.1±26.2 | 0.16 |
| 3% oxygen desaturation index, /h | 28.2±15.6 | 32.7±11.9 | 0.30 |
Values are expressed as mean±SD or median (first–third quartile).
ARB, angiotensin receptor blocker; ASV, adaptive servoventilation; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association.